Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of Ampion for the treatment of severe osteoarthritis of the knee (OAK)

Next Previous
Trial Profile

A clinical study of Ampion for the treatment of severe osteoarthritis of the knee (OAK)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DMI 9523 (Primary)
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 27 Dec 2018 New trial record
  • 13 Dec 2018 According to an Ampio Pharmaceuticals media release, the company will be filing the SPA submission in the near future. The trial is designed to expand by 150 patients (300 total patients) if necessary.
  • 13 Dec 2018 According to an Ampio Pharmaceuticals media release, the US FDA's Office of Tissue and Advanced Therapies (OTAT) has provided final guidance that the company should complete an additional trial of KL4 osteoarthritis patients with concurrent controls that would be carried out under a SPA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top